
    
      In this study, we plan to enroll 30 patients with advanced colorectal cancer after failure of
      second-line standard chemotherapy. The therapeutic regimen is raltitrexed, 3 mg/„é°, ivgtt, d1,
      apatinib 500 mg, qd,po, d1-21, Every 3 weeks for 1 cycles, the primary end point was PFS, the
      secondary end point was OS, DCR, ORR etc. Aim to observe the efficacy and safety of
      raltitrexed combined with apatinib as a third-line treatment of in patients with advanced
      colorectal cancer.
    
  